In the new short week, the Sensex will hover between 49666 and 48111

(Gujarat News Correspondent) Mumbai, Ta. Saturday, January 23, 2021

Amid efforts to get the global economy back on track as the global corona vaccination program is gaining momentum amid the corona epidemic, Indian stock markets set a new record in the Sensex in 2017 and the Nifty in the last week, setting a new level of uptrend. . After a steady upswing in the last 10 months despite the negative factors, the bullish excess is now being calmed down. The change in power in the United States, with uncertainty still lingering on the global front, is now expected to have a positive effect on the steps being taken to get the economy back on track with the Biden government launching massive efforts to stem the tide of Corona's transition. At home in India, next week will be the end of the January trend in derivatives and the start of Parliament's budget session amid preparations for the Union Budget. So in the case of Corona with the budget's expectations, there is a possibility of an index-based phenomenon between development.

Look at Kotak Bank, Larsen, Maruti, Axis Bank, Hindustan Unilever, Cipla now in the corporate results season

In the corporate results season, Reliance Industries' results released on Friday showed a modest increase in profits in the face of declining revenue, but after an overall good time in this challenging time, we will now look at the results to be released next week. In the coming weeks, Kotak Mahindra Bank and Larsen & Toubro will have 4, January 2021 and Axis Bank, Hindustan Unilever will have 4, January 2021 and Maruti Suzuki will have 4, January 2021 and Cipla, Dr. Redtz, Mt. Will keep an eye.

Stock markets to close on January 6: US Federal Reserve meets, looks at Japan's industrial index

The stock markets will be closed next week on the occasion of Republic Day on January 6. On the global front next week, we will be looking at Japan's December 3 industrial production figures and the US Federal Reserve's January 8 meeting in the United States. Amidst these factors-development, the Sensex is likely to fluctuate between 8 and 2111 next week and the Nifty between 19 and 19111.

Dark Horse: Abbott India Ltd.

BSE (2007), NSE (ABBOTINDIA) listed, Rs.10 paid-up, subsidiary of multinational giant Abbott Laboratories with 3% promoter holding established in 1910, 1: 2 shares in year 19, 1: 1 in year 19 7: 6 in Year 12, 1: 1 in Year 13, 1: 1 in Year 13 and 1: 1 in Year 18 Thus with seven bonus issues having 4.5% bonus equity in total equity, Abbott India Limited (ABBOTT INDIA LTD.) High quality trustworthy Medicines is a leading company offering in a range of multiple therapeutic categories such as Women's Health, Gastroenterology, Cardiology, Metabolic Disorders and Primary Care and Medical Devices, including Nutritional Products. Abbott India, one of India's fastest growing pharmaceuticals companies, is part of Abbott's global pharmaceutical business in India.

The company specializes in product development, manufacturing, sales and customer service and provides high quality, reliable products with expert clinical support. The company believes in providing quality healthcare through a combination of global and local products. The company prepares products and clinical development tailored to the unique needs of the Indian market through in-house development and medical teams. Abbott develops and distributes more than 200 products for healthcare professionals in India. The company's products cover medical care and pharmaceutical therapy, from newborns to adults to nutrition and diagnostics. The company has more than 15,000 employees in India and is a market leader in pharmaceuticals, nutrition, devices and diagnostics. More than 150 Abbott scientists carry out research and development to meet specific Indian needs.

Abbott India Chairman and CEO Miles D. "India is an investment priority," White said. India is fundamentally important to Abbott. We are proud of what we are doing in India and we believe that it will have a significant positive impact on the health of Indians. The company has made significant investments in manufacturing plants for its largest business nutritional products and pharmaceuticals. The company meets most of the requirements of its pharmaceutical businesses in its products in India through two local plants, Badi in Himachal Pradesh and Varana in Goa.

The company's top 10 brands are at the forefront of its respective segments and account for 4% of revenue in the Brands division. The company has introduced 31 new product-product extensions in the last year. The company plans to launch 110 new products in the next five years. The Therapy Leading Brands segment accounts for 4% of revenue and has entered into an agreement with Novo-Nordisk to sell insulin products in the domestic market.

Abbott India enables good health with over 500 branded generic pharmaceuticals covering 50 per cent of the therapy area through five lakh pharmacies across the country. The company provides a range of medical devices including blood glucose meters, vascular devices and diagnostic solutions.

Bonus History:

1: 2 shares in Year 12, 1: 1 in Year 12, 1: 2 in Year 12, 2: 3 in Year 12, 1: 1 in Year 12, 1: 1 in Year 13 and 1: 1 in Year 12

Share holding pattern:

Promoters Abbott Capital India Capital 40.5%, Abbott Healthcare Products Ltd. Promoters have a total shareholding of 6.8 per cent, British Colloids Ltd has a total shareholding of 2.7 per cent, foreign portfolio investors have a shareholding of 1.10 per cent and individual shareholders up to Rs 2 lakh have a shareholding of 12.5 per cent. .

Book value:

Rs.5.5 in March 2018, Rs.2.50 in March 2018, Rs.2.5 in March 2018, Rs.2.5 in March 2018, Rs.118.5 in March 2020, Rs.12.05 in expected March 2021

Dividends:

20% in 2014, 200% in 2014, 30% in 2014, 30% in 2014, 200% in 2020

Financial results:

(1) Full year April 2012 to March 2020:

Net income rose to Rs 208 crore from Rs 2.50 crore, net profit rose to Rs 5 crore from Rs 20.5 crore, and earnings per share stood at Rs 4.05.

(2) Second Quarter July 2020 to September 2020:

Net profit rose to Rs 107.8 crore from Rs 107.50 crore and net profit rose to Rs 120.5 crore from Rs 12.5 crore, earning an earnings per share-EPS of Rs 2.08.

(2) First Half Yearly April 2020 to September 2020:

Net income rose to Rs 4,118.15 crore from Rs 206.5 crore, net profit rose 31.50 per cent to Rs 21.05 crore from Rs 4.8 crore, half-yearly earnings per share rose to Rs 15.5 crore 13.5 crore has been achieved.

(2) Expected full year April 2020 to March 2021:

Net profit expected from Rs 2 crore to net profit of Rs 2 crore and earnings per share is expected to be Rs 30.50.

(2) Valuation: B:

MNC Abbott India, which has a 7.5 per cent promoter holding against the average P / E of pharmaceuticals MNC companies, is generally getting a P / E of 9, so if the same P / E is considered, the share could go up to Rs 15. For which the valuation is single B.

Thus, (1) Abbott India Ltd., a leading multinational pharmaceuticals giant holding 7.5 per cent promoters. (3) With a history of seven bonus issues, having a bonus equity of 7.5 per cent. (2) Giving a huge dividend of 200 per cent in the year 2020 alone. (3) The first half of the year from April 2020 to September 2030, net profit of Rs. Achieved half yearly earnings per share of Rs. 18.5 crore from Rs. 18.5 crore to Rs. 21.05 crore with an increase of 1%. (2) Expected full year earnings per share from April 2020 to March 2021 and expected earnings of Rs. The stock is available on NSE, BSE at a price of Rs.

Manoj Shah: Research Analyst (SEBI REG. NO. INH000000107)

The author is a SEBI registered research analyst: Disclosure cum (readers should take special note) Warning: (1) The author has no investment in the shares of the above companies. (3) Our resources for researchers may be of direct or indirect interest, such as broking houses, promoter views, personal research analysts, portfolio management or their team. (3) Maintaining a 30% stop loss from the Reachers price, in particular, is advice and warning. (2) Valuation H, BB, BBB, Top Gainers These are all possibilities, so don't invest temptingly. (2) Generally, out of every 10 scrips, 4 scrips are true and 4-5 scrips are false. (2) Feedback E-mail: All the above points also apply to the answers given in arjuneyems@gmail.com. (2) The reader class, the investor class to take their own personal decisions at personal risk. The writer, editor and anyone of Gujarat Samachar will not be responsible for your loss. So invest by recognizing the risk of the stock market.